Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria gonorrhoeae | 14 | 2023 | 258 | 3.560 |
Why?
|
| Gonorrhea | 11 | 2023 | 196 | 2.990 |
Why?
|
| Complement Factor H | 20 | 2024 | 146 | 2.930 |
Why?
|
| Immunoglobulin Fc Fragments | 8 | 2020 | 48 | 2.570 |
Why?
|
| Recombinant Fusion Proteins | 9 | 2022 | 500 | 1.760 |
Why?
|
| Immunotherapy | 5 | 2020 | 224 | 1.650 |
Why?
|
| Immunoglobulin G | 10 | 2024 | 450 | 1.190 |
Why?
|
| Complement Activation | 4 | 2022 | 53 | 1.130 |
Why?
|
| Bacterial Proteins | 9 | 2023 | 739 | 1.100 |
Why?
|
| Antigens, Bacterial | 13 | 2023 | 211 | 1.020 |
Why?
|
| Bacterial Infections | 2 | 2022 | 139 | 0.870 |
Why?
|
| Complement Pathway, Alternative | 1 | 2022 | 27 | 0.830 |
Why?
|
| Drug Resistance, Multiple | 2 | 2020 | 34 | 0.750 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 22 | 0.730 |
Why?
|
| Bacterial Vaccines | 4 | 2023 | 90 | 0.670 |
Why?
|
| Porins | 5 | 2019 | 79 | 0.660 |
Why?
|
| Neisseria meningitidis | 6 | 2014 | 104 | 0.650 |
Why?
|
| Complement System Proteins | 6 | 2022 | 126 | 0.640 |
Why?
|
| Immune Evasion | 1 | 2019 | 53 | 0.610 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 712 | 0.590 |
Why?
|
| Meningococcal Infections | 2 | 2014 | 27 | 0.560 |
Why?
|
| Lipopolysaccharides | 5 | 2019 | 644 | 0.530 |
Why?
|
| Mice | 19 | 2024 | 10207 | 0.490 |
Why?
|
| Neisseria meningitidis, Serogroup C | 1 | 2014 | 4 | 0.480 |
Why?
|
| Animals | 25 | 2024 | 19516 | 0.450 |
Why?
|
| Streptococcus pyogenes | 3 | 2018 | 27 | 0.430 |
Why?
|
| Meningococcal Vaccines | 4 | 2014 | 28 | 0.400 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2011 | 49 | 0.370 |
Why?
|
| Disease Models, Animal | 6 | 2023 | 2043 | 0.350 |
Why?
|
| Complement C3b | 2 | 2022 | 20 | 0.330 |
Why?
|
| Mice, Inbred BALB C | 8 | 2019 | 880 | 0.320 |
Why?
|
| Streptococcal Infections | 3 | 2018 | 76 | 0.300 |
Why?
|
| Humans | 24 | 2024 | 58948 | 0.280 |
Why?
|
| Protein Binding | 8 | 2018 | 1542 | 0.260 |
Why?
|
| Complement Inactivating Agents | 3 | 2018 | 12 | 0.250 |
Why?
|
| Complement C4b-Binding Protein | 3 | 2019 | 37 | 0.250 |
Why?
|
| Antibodies, Bacterial | 5 | 2023 | 192 | 0.240 |
Why?
|
| Receptors, Fc | 1 | 2024 | 21 | 0.230 |
Why?
|
| Chagas Disease | 1 | 2024 | 34 | 0.230 |
Why?
|
| Amino Acid Substitution | 4 | 2014 | 251 | 0.220 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 49 | 0.220 |
Why?
|
| Properdin | 1 | 2022 | 14 | 0.210 |
Why?
|
| Virulence | 3 | 2018 | 189 | 0.200 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 162 | 0.190 |
Why?
|
| Bacterial Outer Membrane Proteins | 4 | 2018 | 137 | 0.180 |
Why?
|
| Mice, Transgenic | 6 | 2024 | 1219 | 0.170 |
Why?
|
| Virulence Factors | 2 | 2018 | 83 | 0.170 |
Why?
|
| Blood Bactericidal Activity | 2 | 2011 | 70 | 0.170 |
Why?
|
| Binding Sites | 3 | 2016 | 872 | 0.170 |
Why?
|
| Sialic Acids | 2 | 2017 | 46 | 0.170 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 112 | 0.170 |
Why?
|
| Histocompatibility Antigens | 1 | 2019 | 107 | 0.170 |
Why?
|
| Peptides | 2 | 2019 | 546 | 0.160 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 6 | 0.160 |
Why?
|
| Fimbriae, Bacterial | 1 | 2019 | 19 | 0.160 |
Why?
|
| Female | 12 | 2023 | 30624 | 0.160 |
Why?
|
| Complement Inactivator Proteins | 1 | 2008 | 9 | 0.150 |
Why?
|
| Complement Pathway, Classical | 1 | 2008 | 23 | 0.150 |
Why?
|
| Staphylococcal Vaccines | 1 | 2017 | 2 | 0.150 |
Why?
|
| Haemophilus influenzae | 1 | 2016 | 26 | 0.130 |
Why?
|
| Pan troglodytes | 2 | 2011 | 35 | 0.130 |
Why?
|
| Haemophilus Infections | 1 | 2016 | 15 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2016 | 99 | 0.130 |
Why?
|
| Species Specificity | 2 | 2011 | 335 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1228 | 0.120 |
Why?
|
| Drug Design | 1 | 2016 | 143 | 0.120 |
Why?
|
| Blood | 1 | 2014 | 27 | 0.120 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 56 | 0.120 |
Why?
|
| Microbial Viability | 1 | 2014 | 56 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 4 | 2024 | 864 | 0.120 |
Why?
|
| Rats, Wistar | 1 | 2014 | 178 | 0.110 |
Why?
|
| Neoplasms | 1 | 2024 | 1221 | 0.110 |
Why?
|
| Epitopes | 3 | 2019 | 298 | 0.110 |
Why?
|
| Complement C3-C5 Convertases, Alternative Pathway | 1 | 2013 | 5 | 0.110 |
Why?
|
| Meningitis, Meningococcal | 1 | 2013 | 10 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2016 | 667 | 0.110 |
Why?
|
| Sepsis | 1 | 2017 | 278 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 661 | 0.110 |
Why?
|
| Bacteria | 1 | 2016 | 275 | 0.110 |
Why?
|
| Bacteremia | 1 | 2011 | 94 | 0.090 |
Why?
|
| Vagina | 2 | 2023 | 82 | 0.090 |
Why?
|
| Arginine | 1 | 2011 | 113 | 0.090 |
Why?
|
| Heparin | 1 | 2011 | 113 | 0.090 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 70 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 253 | 0.080 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1576 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1972 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1113 | 0.070 |
Why?
|
| Phagocytosis | 2 | 2018 | 252 | 0.070 |
Why?
|
| Macaca mulatta | 2 | 2014 | 246 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 2 | 2016 | 233 | 0.060 |
Why?
|
| Half-Life | 1 | 2024 | 70 | 0.060 |
Why?
|
| Gram-Positive Bacteria | 1 | 2024 | 36 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 2024 | 54 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2014 | 5116 | 0.060 |
Why?
|
| Mutation | 1 | 2011 | 2420 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2024 | 130 | 0.050 |
Why?
|
| Cell Division | 1 | 2023 | 441 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3168 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 72 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 138 | 0.040 |
Why?
|
| Papio | 1 | 2008 | 12 | 0.040 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 2017 | 5 | 0.040 |
Why?
|
| Oligosaccharides | 1 | 2008 | 62 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 151 | 0.040 |
Why?
|
| Complement C3 | 1 | 2017 | 61 | 0.040 |
Why?
|
| Neisseria | 1 | 2016 | 6 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 35 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2008 | 350 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 197 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2018 | 714 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2090 | 0.030 |
Why?
|
| Rabbits | 1 | 2013 | 330 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 304 | 0.030 |
Why?
|
| Serum Bactericidal Antibody Assay | 1 | 2012 | 8 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 819 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2011 | 18 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2011 | 101 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 281 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 183 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 688 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 228 | 0.020 |
Why?
|
| Immunity | 1 | 2010 | 96 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1904 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 764 | 0.020 |
Why?
|
| Male | 2 | 2018 | 27335 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1535 | 0.010 |
Why?
|
| Adult | 1 | 2011 | 15632 | 0.010 |
Why?
|